Crispr Therapeutics AG (CRSP) stock has gained 89.99% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives CRSP stock a score of 34 out of a possible 100.
That rank is mainly influenced by a short-term technical score of 23. CRSP's rank also includes a long-term technical score of 26. The fundamental score for CRSP is 53. In addition to the average rating from Wall Street analysts, CRSP stock has a mean target price of 163.8. This means analysts expect the stock to gain 29.98% over the next 12 months.
What's Happening with CRSP Stock Today
Crispr Therapeutics AG (CRSP) stock has risen 1.7% while the S&P 500 has gained 0.11% as of 2:03 PM on Thursday, Jun 17. CRSP has gained $2.11 from the previous closing price of $123.91 on volume of 767,636 shares. Over the past year the S&P 500 is higher by 35.81% while CRSP has gained 89.99%. CRSP lost -$5.62 per share in the over the last 12 months.
Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.
